Year: 2021

AVENTURA, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) — Life Clips, Inc. (OTC Pink: LCLP) (the “Company”) announced today that Robert Grinberg, CEO issued a letter to Life Clips’ shareholders. The full text is as follows: To My Fellow Stockholders, It was eight months ago when I issued my first Letter to Shareholders. Since then, we have gained many new shareholders and acquired two unique companies. The first, Cognitive Apps Software Solutions Inc., (Cognitive Apps) a developer of artificial intelligence (AI) applications for the healthcare and mental health industries. The second, Belfrics, a global fintech firm with its own blockchain and cryptocurrency exchange and a multi-feature trading platform for digital assets and cryptocurrencies. I believe that we are one of an elite group of companies worldwide that could potentially...

VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111) TEL AVIV, Israel and NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it has been selected for €17.5 million of blended funding by the European Innovation Council (EIC) Accelerator. The funding is comprised of a €2.5 million grant and an additional €15 million direct equity investment by the EIC. The EIC Accelerator is a prestigious competitive program of the European Commission, which offers grants combined with equity investments...

JI XING to Develop and CommercializeNovel Cardiac Myosin Activator in Patients with Heart Failure Cytokinetics to Receive $70 Million in Committed Capital;Up to an Additional $330 Million in Potential Milestone Payments Plus Royalties Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., and SHANGHAI, China, Dec. 20, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) and Ji Xing Pharmaceuticals Limited (JI XING), a biopharmaceutical company based in Shanghai and backed by RTW Investments, LP (RTW), today announced an expansion of their collaboration by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the proposed treatment of heart failure with reduced ejection fraction (HFrEF) in Greater China....

— Clinical development of the MYC repressor APTO-253 will be discontinued — — Company will focus on advancing kinome inhibitor pipeline — SAN DIEGO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced its decision to discontinue further clinical development of APTO-253. The decision follows prioritization of the company’s other more advanced pipeline candidates, as well as an internal review of the product profile and performance to date of APTO-253, including a clinical hold placed by the U.S. Food & Drug Administration. “We plan to enter the new year 2022 focused exclusively on the swift development of our kinome inhibitors HM43239 and luxeptinib, both of which recently have demonstrated encouraging clinical activity in challenging...

CANTON, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the largest omni-channel specialty retailer of big and tall men’s clothing and shoes, announced today that on Friday, December 17th, it appointed Carmen R. Bauza, 59, to the Company’s Board of Directors. She will serve as a director until the Company’s next annual meeting of stockholders, at which time she will stand for re-election. With her appointment, the size of the Company’s Board of Directors is seven members. Ms. Bauza is currently on the board of managers for privately-owned retailer Claire’s Stores Inc. “We are excited to welcome Carmen to the board,” said President and CEO Harvey S. Kanter. “She will bring her expertise gathered over 30 years in retail focused on growth opportunities at Walmart, HSN and Fanatics. Carmen’s extensive retail experience will...

MONTREAL, Dec. 20, 2021 (GLOBE NEWSWIRE) — Vision Marine Technologies, Inc. (NASDAQ: VMAR) (“Vision Marine” or the “Company”), the global leader in the electric transition of the recreational boating industry serving both OEMs and consumers, announced today that its Board of Directors has authorized the repurchase of up to 10% of the Company’s common shares from time to time via open market purchases or in privately negotiated transactions. “We believe that our shares represent a unique value driven opportunity, as the boating industry is at a critical inflection point regarding the transition to clean, cost effective zero carbon emission watercraft. Our disruptive technology puts Vision Marine at the forefront of this timely movement,” stated Alan Gaines, Chairman of the Board of the Company. “The recent investment...

CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Derek Hicks to a newly created position as Executive Vice President, Chief Business Officer. Mr. Hicks joins Intellia with more than 25 years of combined business, leadership and biotechnology experience, having most recently served as Head of Business Development at Spark Therapeutics. While at Spark, he was responsible for business development strategy, search and evaluation, licensing and key partnership activities. Prior to this role, Mr. Hicks spent 18 years at Pfizer in a variety of business and corporate development roles culminating with his position as Vice President,...

CONFERENCE CALL TO BE HELD ON JANUARY 27, 2022 AT 2:00PM ET NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that it will release its earnings for the fourth quarter of 2021 on Wednesday, January 26, 2022 after market close. The Company’s executive management team, led by Marc Holliday, Chairman and Chief Executive Officer, will host a conference call and audio webcast on Thursday, January 27, 2022 at 2:00 pm ET to discuss the financial results. Simultaneous with the earnings release, supplemental data will be made available in the Investors section of the SL Green Realty Corp. website at https://slgreen.com/ under “Financial Reports”. The live conference call will be webcast in listen-only mode in the Investors section of the SL Green Realty...

Company to Also Host Fireside Chat at the 24th Annual ICR Conference on January 10, 2022 NEW YORK and LEAMINGTON, Ontario, Dec. 20, 2021 (GLOBE NEWSWIRE) — Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY; TSX: TLRY) announced that the Company will release financial results for its second quarter fiscal 2022 ended November 30, 2021 before financial markets open on January 10, 2022. Tilray executives will host a conference call and live audio webcast to discuss these results at 8:30 am Eastern Time, details of which are provided below. Live Conference Call and Audio Webcast: Date/Time: Monday, January 10, 2022 at 8:30 am Eastern Time. Call-in Number: (877) 407-0792 from Canada and the U.S. or (201) 689-8263 from international locations. Please dial in at least 10 minutes prior to the start time. A telephone replay will be...

Product is now available exclusively through Anovo specialty pharmacy Product is stable at room temperature while Carbaglu® requires refrigeration Eton Cares patient support program will offer $0 co-pays to commercial insurance patientsDEER PARK, Ill., Dec. 20, 2021 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutical company serving patients in need through the development and manufacturing of high-quality generic and branded medicines, today announced the commercial launch of Carglumic Acid tablets. The product will be marketed by Eton Pharmaceuticals and is the first and only FDA-approved generic version of Carbaglu®. It was approved by the FDA...